Navigation Links
NIAID funds clinical trials that address the problem of antimicrobial resistance
Date:9/2/2009

Scientists are addressing the threat of antimicrobial drug resistance by launching two new clinical trials aimed at prolonging the effectiveness of currently available antibacterial drugs. The concept underlying both studies: Less is more.

The six-year contracts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are part of an initiative intended to help answer key questions about proper antimicrobial doses, treatment duration and whether antimicrobial treatment is necessary in all cases. NIAID has made an initial award of $1.5 million to the Children's Hospital of Philadelphia with further funding of up to a total of $13.8 million available over the six-year course of the contract if clinical trial milestones are met. Duke University, Durham, N.C., has received an initial award of $1.4 million. If milestones are met, the total award from NIAID to the Duke team could total up to $11 million over six years.

Many infectious diseases are increasingly difficult to treat because bacteria and other microbes have developed resistance to commonly used antimicrobial drugs. Microbial drug resistance is driven by a variety of forces, including expanded use of antimicrobial drugs in human and animal healthcare. According to one estimate, between 5 and 10 percent of all hospitalized patients in the United States develop a drug-resistant infection of some kind, leading to an added $5 billion in annual healthcare costs.

"The clinical trials supported by this important initiative will provide vital information on the optimal use of antimicrobial drugs in a variety of clinical settings," says NIAID Director Anthony S. Fauci, M.D. "This information is critical to improving patient care and slowing the development of drug resistance."

Reducing the risk of antimicrobial resistance is a priority for NIAID, as exemplified by these new trials and two similar studies now under way. NIAID has also intends to fund additional innovative proposals aimed at slowing the development of antimicrobial resistance through targeted clinical trials. "Historically, development of new antimicrobials has moved at a much slower pace than the evolution of resistance to those treatments, so we need to look at preserving the usefulness of the drugs we have," says Dennis M. Dixon, Ph.D., chief of the Bacteriology and Mycology Branch within NIAID's Division of Microbiology and Infectious Diseases. "One way to reduce the risk of resistance, and therefore to preserve antimicrobials, is to reduce unnecessary use of these drugs."

In the new round of research, investigators at Children's Hospital of Philadelphia will study children with urinary tract infections to determine if treatment with antimicrobials can be shortened from the standard length of up to two weeks and still be effective. The study will enroll as many as 1,000 children.

The Duke study also will test the effectiveness of shorter duration of antimicrobial treatment. This project will focus on hospitalized patients who acquire staphylococcal infections in the bloodstream after use of an intravenous catheter. This study could lead to reduced drug exposure in patients with such infections, which in turn lowers the chance that bacteria will develop resistance to the drugs. The conditions studied in these trialsinfections in the urinary tract or the bloodstreamare ones where development of antimicrobial resistance is of particular concern.

Christine Chiou, M.D., is the NIAID program officer overseeing the projects at Children's Hospital of Philadelphia and at Duke. The projects are part of a second round of funding to support research on optimal ways to treat bacterial infections while minimizing development of antimicrobial resistance. The first awards were made in 2007 to the University of California, Los Angeles, and the University of California, San Francisco (http://www3.niaid.nih.gov/news/newsreleases/2007/ca-mrsa_contracts.htm).


'/>"/>

Contact: NIAID Office of Communications
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
2. NIAID to fund new human immune profiling research centers
3. NIAID media availability: Still searching for predictors of asthma attacks
4. NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates
5. NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
6. J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases
7. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
8. NIAID honors AIDS activist Martin Delaney
9. NIAID media availability: Seizures following parasitic infection associated with brain swelling
10. NIAID awards contracts to search for protein markers of disease
11. NIAID creates HIV vaccine discovery branch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set ... one video to the next without having to set a single keyframe in ... to enhance your video production. , TransDark features dynamic transitions that momentarily splits the ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... An April 24th article on ... stunning 180 pounds with the help of a weight loss surgery. The woman, declaring “I ... skin that have been left following her dramatic weight loss. Dr. Feiz & Associates notes ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Beginning in 2017, ... their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure that ... the formula in the following ways:, , Removal of the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology: